Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    82,969.52
    -2,977.47 (-3.46%)
     

  • CMC Crypto 200

    1,259.95
    -98.06 (-7.22%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 22, 2021 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - November 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) alleging that the Company violated federal securities laws.

Class Period: January 13, 2020 to September 3, 2021
Lead Plaintiff Deadline: December 22, 2021
No obligation or cost to you.

Learn more about your recoverable losses in BMRN:
https://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?id=21600&from=5

BioMarin Pharmaceutical Inc. NEWS - BMRN NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in BioMarin you have until December 22, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased BioMarin securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the BMRN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105414